neoag
Neoantigen × AI
Daily research signal
№48Brief2026-07-30

Interim Analysis Shows Safety Of Personalized Neoantigen Vaccines

A new interim analysis of personalized Neo-DC vaccination in solid tumors provides early clinical safety and efficacy signals, while a pan-cancer study identifies immunoproteasome components as key prognostic markers for neoantigen processing.PubMedPubMed

Concurrently, a review highlights the critical role of nano-delivery systems and combination strategies in overcoming current barriers to breast cancer vaccine adoption.PubMed

1new story2 in context
ClinicaltodayNew

Safety and Preliminary Efficacy of Personalized Neoantigen-pulsed Dendritic Cell Vaccination in Patients With Solid Tumors: An Interim Analysis.

An interim analysis of personalized neoantigen-pulsed dendritic cell (Neo-DC) vaccination in advanced solid tumors reports on the tolerability and preliminary efficacy of this approach. The study enrolled patients with confirmed solid malignancies, utilizing next-generation sequencing to identify tumor-specific neoantigens with high MHC affinity for pulsing autologous dendritic cells. As of November 2025, 36 patients were registered with 27 receiving vaccination, offering early clinical data on this personalized immunotherapy modality.

Dendritic-cell vaccines
europepmc · today · Takimoto R, Kamigaki T, Okada S, Ibe H, Oguma E, Ohno A, Naito K, Yoshida Y, Narimiya S, G

Catching up02

Relevant work from earlier we're still surfacing — not today's news.

Explore the field

Field MapTrialsPrimer